2019-11-20 08:20
The study is a retrospective analysis on serum samples from a randomized clinical trial comprising 644 women with operable breast cancer (premenopausal with stage II-IIIB HR+ breast cancer). Serum samples were collected pre-operatively on the day of surgery...
2019-11-20 08:00
The prognostic value of DiviTum was assessed in a prospective study of 103 metastatic breast cancer patients treated from May 2016 until August 2018 at Institut Curie, Paris, with endocrine therapy and the CDK4/6 inhibitor palbociclib. Plasma samples...
2019-11-15 08:00
Otti Bengtsson Gref has a long experience of leading positions in the R&D field in the commercial diagnostic industry. Otti most recently comes from the role as R&D Director at Cavidi. She has held various managerial positions in R&D at IDD...
2019-10-25 11:28
“The renewal of the certificate is important for Biovica as it proves that our quality management system fulfills the global quality requirements. The quality management system is a pre-requisite for market approval in both US and Europe and hence...
2019-10-03 08:45
At the conference, Pontus Nobréus will address how liquid biomarkers can contribute with fundamental information and to a more effective process in the development of oncology drugs. DiviTum® is a cell proliferation biomarker and a valuable...
2019-09-18 08:00
The presentation will be held in English and will be followed by a questions and answers session. Questions can be asked via the telephone conference or in written form via the audiocast. No pre-registration is needed. Participant dial in number DK: +4578150109...
2019-09-18 08:00
Under the agreement, the DiviTum® blood assay will be used to analyze blood samples taken from participants in S0226, which between 2004 and 2009 enrolled 707 postmenopausal women with metastatic breast cancer at 73 hospitals, clinics, and cancer...
2019-09-17 08:00
The authors depicture the biological drivers behind CDK4/6 resistance, succeeded by how DiviTumÒ can contribute to identifying patients where an early switch to an alternative treatment can improve patient outcome and support treatment decisions...
2019-08-29 08:00 Regulatory Interim
Significant events during the first quarter Significant events after the end of the period CEO’s comments Commercialization of DiviTum® for breast cancer During the first quarter of the new financial year, we achieved several important milestones...
2019-08-28 07:55
Based on the feedback from the FDA, Biovica has now a clear path to a 510(k) submission and clearance for DiviTum. In the supplement II process, topics such as intended use, clinical validation plan and predicate device were discussed. This is the third...

>4,500

Numbers of patients in studies

28

Publications

22

Pharma Projects

Are you a US resident?

Only US residents will be able to qualify for this program

No